⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Santhera Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Santhera Pharmaceuticals
↗Pratteln, Switzerland
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company founded in 1998 and headquartered in Pratteln, Switzerland. The company focuses on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera's lead product, AGAMREE (vamorolone), is a first-in-class dissociative steroid approved by the FDA, EMA, MHRA, NMPA, and other regulatory agencies for Duchenne muscular dystrophy (DMD). The company employs approximately 85 people and operates through a global network of commercial partnerships.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals - Rare Neuromuscular and Pulmonary Diseases
SIZE & FINANCIALS
Employees:51-200
Revenue:CHF 24M H1 2025 (trending towards CHF 130-140M+ FY 2025)
Founded:1998
Ownership:public
Status:operating
FUNDING
Stage:Public Company
STOCK
Exchange:SIX Swiss Exchange
Ticker:SANN
Market Cap:$305M (CHF 305M as of Feb 2026)
PIPELINE
Stage:Commercial/Phase 2
Lead Drug Stage:FDA Approved (AGAMREE for DMD)
Modalities:Small molecule, Gene therapy
Active Trials:2
Trial Phases:Phase 2: 1 | Phase 4: 1
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:Catalyst Pharmaceuticals (North America distribution and commercialization), Nxera Pharma (Japan, South Korea, Australia, New Zealand - up to USD 205M deal), Sperogenix (China), Clinigen Group (distribution/supply), ReveraGen BioPharma (original vamorolone licensor), SEAL Therapeutics (LAMA2 gene therapy)
COMPETITION
Position:Leader
Competitors:Sarepta Therapeutics (ELEVIDYS, exon-skipping therapies), PTC Therapeutics (aminoglycoside read-through inducer), Italfarmaco (Givinostat), FibroGen (Pamrevlumab), Capricor (CAP-1002), Solid Biosciences, Taiho Pharmaceutical (TAS-205)
LEADERSHIP
Key Executives:
Dario Eklund - Chief Executive Officer
Catherine Isted - Chief Financial Officer
Marc Schrader - Chief Technology Officer
Marc Clausse - Chief Commercial Officer
Thomas Meier - Chairman & Director
Scientific Founders:Thomas Meier
Board Members:Thomas Meier (Chairman), Dr. Melanie Rolli (elected May 2025), Bradley C. Meyer (Compensation Committee Chairman)
LINKS
Website:santhera.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Santhera Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.